In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Vertex Pharmaceuticals VRTX, and raised the price target from $75.00 to $100.00.
In the report, Karnauskas noted, “661 data released today beat our positive expectations. We now model c100% success in F508del homozygous (prev. 75%) and 100% success in other Kalydeco mutations (prev. 50%), and increase market size oppy for other mutations. We also see oppy's for upside leading to VRTX FVs of $100-$150/sh. We are increasing our TP to $100 for the reasons above and reiterate our Buy rating.”
Vertex Pharmaceuticals closed on Thursday at $52.87.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in